EMCC: AZURE Subgroup Analysis Shows Adjuvant Therapy With Zoledronic Acid May Benefit Breast Cancer Patients Postmenopausal > 5 Years

Publication
Article
OncologyONCOLOGY Vol 25 No 12
Volume 25
Issue 12

Results of the AZURE trial revealed small improvements in disease-free and overall survival when zoledronic acid was used in addition to adjuvant therapy in a subgroup of early-stage breast cancer patients who had been postmenopausal for more than 5 years.

Reporting complete results of the AZURE trial online in the New England Journal of Medicine on September 25, researchers concluded that the bisphosphonate zoledronic acid (Zometa [ZA]) should not be used routinely in adjuvant management of breast cancer. In what they described as an "intriguing" finding, however, small improvements in disease-free and overall survival (DFS, OS) were seen with the addition of ZA to adjuvant therapy in a subgroup of early-stage breast cancer patients who had been postmenopausal for more than 5 years.

AZURE lead investigator Robert E. Coleman, MB, BS, MD, from the Weston Park Hospital, Sheffield, United Kingdom, presented the findings at the European Multidisciplinary Cancer Congress (EMCC; abstract 5019) in Stockholm, on September 26.

In AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence), an open-label phase III study of patients from 174 cancer centers, 3,360 women with stage II or III breast cancer were randomly assigned to receive standard chemotherapy and/or endocrine therapy, with or without ZA. The ZA was given every 3 to 4 weeks for 6 doses and then every 3 to 6 months to complete 5 years of treatment. DFS was the primary end point of the study. A second interim analysis showed that a prespecified boundary for lack of benefit had been crossed.

At a median follow-up of 59 months, each group had a DFS rate of 77% (adjusted hazard ratio [HR] in the ZA group, 0.98; 95% confidence interval [CI], 0.85–1.13; P = .79). Disease recurrence or death occurred in 377 patients in the ZA group, vs 375 women in the control group. OS rates of 85.4% and 83.1% were seen in the ZA and control groups, respectively (adjusted HR, 0.85; 95% CI, 0.72–1.01; P = .07).

Yet among women who had gone through menopause more than 5 years earlier (a subgroup representing about one-third of the total study population), the 5-year OS rate in the ZA group (n = 519) was 84.6% vs 78.7% in the control group (n = 522) (adjusted HR, 0.74; 95% CI, 0.55–0.98; P = .04). Among the other patients, OS rates were 85.7% in the ZA group and 85.1% in the control group (adjusted HR, 0.97; 95% CI, 0.78–1.21; P = .81). The differences were independent of estrogen-receptor status, tumor stage, and lymph-node involvement.

In their article in NEJM, the authors wrote, "In a prespecified analysis, our finding of a possible benefit of [ZA] in patients who had undergone menopause more than 5 years before study entry is intriguing…and showed a small but significant survival advantage for patients who received [ZA]. Furthermore, the use of [ZA] appeared to have divergent effects on metastasis to visceral and locoregional sites according to menopausal status." Analyses of the findings "suggest a systemic effect of [ZA] that operates differently according to menopausal status and that is distinct from any effect in bone," they said, hypothesizing that "perhaps bone provides a sanctuary for cancer cells, and after treatment with [ZA], the ability of cancer cells to disseminate to other body sites is dependent on the presence of reproductive hormones."

Recent Videos
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.